System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 19 citations

PubMed: 39806516 DOI: 10.1186/s13045-024-01634-6

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

J Hematol Oncol 18(1):6

Authors: Antonino Glaviano, Hannah Si-Hui Lau, Lukas M Carter, E Hui Clarissa Lee, Hiu Yan Lam, Elena Okina, Donavan Jia Jie Tan, Wency Tan, Hui Li Ang, Daniela Carbone, Michelle Yi-Hui Yee, Muthu K Shanmugam, Xiao Zi Huang, Gautam Sethi, Tuan Zea Tan, Lina H K Lim, Ruby Yun-Ju Huang, Hendrik Ungefroren, Elisa Giovannetti, Dean G Tang, Tullia C Bruno, Peng Luo, Mads Hald Andersen, Bin-Zhi Qian, Jun Ishihara, Derek C Radisky, Salem Elias, Saurabh Yadav, Minah Kim, Caroline Robert, Patrizia Diana, Kurt A Schalper, Tao Shi, Taha Merghoub, Simone Krebs, Anjali P Kusumbe, Matthew S Davids, Jennifer R Brown, Alan Prem Kumar

Affiliations

  • Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, 90123, Palermo, Italy.
  • Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117597, Singapore.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore.
  • NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore.
  • School of Chemical and Life Sciences, Singapore Polytechnic, Singapore, 139651, Singapore.
  • Cancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
  • Immunology Program, Life Sciences Institute, National University of Singapore, Singapore, 117456, Singapore.
  • Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore.
  • School of Medicine and Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
  • Department of Obstetrics & Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117456, Singapore.
  • First Department of Medicine, University Hospital Schleswig-Holstein (UKSH), Campus Lübeck, 23538, Lübeck, Germany.
  • Department of Medical Oncology, Cancer Center Amsterdam, UMC, Vrije Universiteit, HV Amsterdam, 1081, Amsterdam, The Netherlands.
  • Cancer Pharmacology Lab, Fondazione Pisana Per La Scienza, 56017, San Giuliano, Italy.
  • Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Experimental Therapeutics (ET) Graduate Program, University at Buffalo & Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Department of Immunology, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • National Center for Cancer Immune Therapy, Department of Oncology, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, The Human Phenome Institute, Zhangjiang-Fudan International Innovation Center, Fudan University, Shanghai, China.
  • Department of Bioengineering, Imperial College London, London, W12 0BZ, UK.
  • Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, 32224, USA.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
  • Department of Cancer Medicine, Inserm U981, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France.
  • Faculty of Medicine, University Paris-Saclay, Kremlin Bicêtre, Paris, France.
  • Department of Pathology, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
  • Sandra and Edward Meyer Cancer Center, Department of Medicine, Parker Institute for Cancer Immunotherapy, Weill Cornell Medicine, New York, NY, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Tissue and Tumor Microenvironment Group, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117600, Singapore.
  • NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119228, Singapore.

Abstract

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote tumor growth and therapeutic resistance. Elucidating the intricate interactions between cancer cells and the TME is crucial in understanding cancer progression and therapeutic challenges. A critical process induced by TME signaling is the epithelial-mesenchymal transition (EMT), wherein epithelial cells acquire mesenchymal traits, which enhance their motility and invasiveness and promote metastasis and cancer progression. By targeting various components of the TME, novel investigational strategies aim to disrupt the TME's contribution to the EMT, thereby improving treatment efficacy, addressing therapeutic resistance, and offering a nuanced approach to cancer therapy. This review scrutinizes the key players in the TME and the TME's contribution to the EMT, emphasizing avenues to therapeutically disrupt the interactions between the various TME components. Moreover, the article discusses the TME's implications for resistance mechanisms and highlights the current therapeutic strategies toward TME modulation along with potential caveats.

MeSH

Cells, Hematology, Epithelial-Mesenchymal Transition, Neoplasms, Neoplasm Metastasis, Therapeutics, Tumor Microenvironment

Cited by